1. - a Pharmaceutical Combination comprising an Antibody that specifically recognizes at least CD38 and vincristine, which said Antibody can destroy a cell CD38 + by apoptosis, Antibody dependent Cell mediated cytotoxicity (ADCC) and dependent cytotoxicity Complement (CDC) 2.- The combination of claim 1, in which the Antibody is an Antibody humanizado.3.- The combination of claim 2, in which the Antibody comprising one or more of the complementarity determining regions which has an Amino Acid Sequence is selected from the group consisting of SEQ ID: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 and 36.4.- The combination of claim 3, which comprises at least one such Antibody heavy chain and at least a light chain, in which the heavy chain has an Amino Acid Sequence represented by SEQ ID no: 66And the heavy chain comprises three regions Sequential determinants of complementarity with the Amino Acid Sequence represented by the SEQ ID Nos: 13, 14 and 15, and in the light chain is the Amino Acid Sequence is selected from the group of SEQ ID Nos: 62 and 64,And the light chain comprises three regions of complementarity that Sequential determinants have amino acid sequences represented by SEQ ID Nos: 16, 17 and 18.1.- Una combinación farmacéutica que comprende un anticuerpo que reconoce específicamente CD38 y al menos vincristina, en la que dicho anticuerpo puede destruir una célula CD38+ por apoptosis, citotoxicidad mediada por células dependientes de anticuerpos (ADCC) y citotoxicidad dependiente del complemento (CDC).2.- La combinación de la reivindicación 1, en la que dicho anticuerpo es un anticuerpo humanizado.3.- La combinación de la reivindicación 2, en la que dicho anticuerpo comprende uno o más regiones determinantes de la complementariedad que tiene una secuencia de aminoácidos seleccionada del grupo constituido por las SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
